arXiv:2606.00555v2 Announce Type: replace Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together. To quantify this...
Les hele artikkelen hos kilden.
Kommentarer (0)
Ingen kommentarer ennå. Bli den første til å kommentere!